When is omeprazole indicated for use with apixaban (Eliquis)?

Omeprazole Use with Apixaban (Eliquis)

Omeprazole is indicated with apixaban when patients are at increased risk of gastrointestinal bleeding, particularly those who are elderly, have a history of GI bleeding or peptic ulcer disease, use chronic NSAIDs or steroids, consume high amounts of alcohol, or are receiving combination antithrombotic therapy. 1

Risk Factors Requiring GI Protection

Proton pump inhibitors, including omeprazole, should be used for gastric protection in patients on apixaban who have:

• History of upper GI bleeding or peptic ulcer disease (highest priority)
• Age ≥65-75 years
• Chronic NSAID or corticosteroid use
• High alcohol consumption
• Combination antithrombotic therapy (apixaban plus antiplatelet agents)
• Multiple risk factors present simultaneously

1

Key Clinical Context

The 2024 ESC guidelines explicitly state that gastric protection with proton pump inhibitors is recommended in patients at increased risk of GI bleeding for as long as any antithrombotic therapy is administered 1. This applies to apixaban despite it being an anticoagulant rather than an antiplatelet agent.

Important Distinction from Clopidogrel

Unlike clopidogrel, there is no clinically significant drug interaction between omeprazole and apixaban. The concern about omeprazole inhibiting CYP2C19 is specific to clopidogrel metabolism 2, 1. Apixaban is metabolized primarily by CYP3A4/5 (not CYP2C19) and is a P-glycoprotein substrate 3. While one rat study suggested potential pharmacokinetic changes 4, this has not translated to clinically meaningful interactions in human studies or guidelines.

When NOT to Use Omeprazole with Apixaban

Routine prophylactic use is not recommended in patients at lower risk of upper GI bleeding who lack the risk factors listed above 1. The decision should be based on individual bleeding risk assessment rather than reflexive prescription.

Practical Application

For patients on apixaban:

1. Assess GI bleeding risk factors at initiation and periodically
2. Initiate omeprazole (or another PPI) if ≥1 major risk factor or ≥2 minor risk factors present
3. Continue PPI therapy for the entire duration of anticoagulation if risk factors persist
4. No dose adjustment of apixaban is needed when combined with omeprazole

The evidence strongly supports PPI use for reducing GI bleeding risk in patients on various antithrombotic therapies, with a demonstrated 50% reduction in upper GI bleeding 5. This benefit applies to apixaban users at increased risk, making omeprazole a reasonable gastroprotective strategy in appropriate patients.